References

  1. DynamX Mechanistic Clinical Study, presented CRT 2020
  2. Calculated based on lumen area increase between systole and diastole – Hagen-Poiseuille equation.

  3. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S. Comparison of zotarolimus‐ and everolimus‐eluting coronary stents: final 5‐year report of the RESOLUTE all‐comers trial. Circ Cardiovasc Interv. 2015; 8:e002230.

  4. Gyöngyösi M, Yang P, Khorsand A, et al. Longitudinal Straightening Effect of Stents Is an Additional Predictor for Major Adverse Cardiac Events. J Am Coll Cardiol 2000;35:1580-9.
  5. LTFU after 81 Days

  6. LTFU after 304 Days

  7. Data on file at Elixir Medical

  8. COVER-OCT Trial – Kim et al. Am Heart J 2012; 163:601

  9. Resolute all Comers: Gutierrez-Chico et al EHJ, 2011; 32:2454

  10. DESSOLVE-1 Trial – Attizzani et al. Am J Cardiol 2013; 112-1557

  11. Iqbal, J, Verheye, S, Abizaid, A, Ormiston, J, de Vries, T, Morrison, L & Serruys, PW. DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016;12(11), e1336

  12. Chien S. Am J Physiol Heart Circ Physiol. 2007; 292: H1209-H1224.

  13. Stone GW, Kimura T, Gao R, et al. JAMA Cardiol. 2019 Dec 1;4(12):1261-1269.

  14. Kufner S, Joner M, Thannheimer A, et al. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease – Results From the ISAR-TEST 4 Randomized Trial. Circulation. 2019;139:325–333.
  15. Verheye S, Vrolix M, Montorfano M, et al. Twelve-month clinical and imaging outcomes of the uncaging DynamX Bioadaptor System. EuroIntervention 2020; Jaa-835, 2020, doi: 10.4244/EIJ-D-20-00763.

  16. Serruys P, et al,  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial., EuroIntervention 2006.

  17. Meredith IT, et al, Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC (2009).

  18. Meredith IT, Whitbourn R, Scott D, et al, PLATINUM QCA: EuroIntervention. 2011.

  19. Windecker, S. et al, (LEADERS): a randomised non inferiority trial; The Lancet 2008; 372 No. 9644: 1163-1173.

  20. Windecker S. et al, BioFlow II Trail, Circulation: Cardiovascular Intervention 2015.

  21. Meredith IT, Primary Endpoint Results of the EVOLVE Trial: A Randomized Evaluation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent, 2012.

  22. DynamX Mechanistic Clinical Study 24 Month Results, presented Singapore Live 2021
  23. LTFU after 344 Days; 2 missed visits

PMN 594 Rev B

Elixir-Medical-Corporation-Coronary-Device

Corporate Headquarters
920 N. McCarthy Blvd
Milpitas, CA 95035 U.S.
+1.408.636.2000
info@elixirmedical.com

Elixir, Innovation for Life and DESyne are registered trademarks, and DynamX a trademark, in the US and internationally for Elixir Medical Corporation.
DynamX Coronary Bioadaptor System and DESyne X2 Novolimus Eluting Coronary Stent System are CE Mark approved.
©2020 Elixir Medical. All rights reserved.
International (OUS) Use Only. DynamX and DESyne X2 are intended to improve coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

Sign up to receive news and information about Elixir Medical, our products and other relevant information as it becomes available.